Symbols / IOVA Stock $3.43 -0.29% Iovance Biotherapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
IOVA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Exch · Country NGM · United States
Market Cap 1.41B
Enterprise Value 1.17B
Income -390.98M
Sales 263.50M
FCF (ttm) -162.42M
Book/sh 1.70
Cash/sh 0.72
Employees 975
Insider 10d —
IPO Oct 15, 2010
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -12.33
PEG —
P/S 5.36
P/B 2.02
P/C —
EV/EBITDA -3.22
EV/Sales 4.42
Quick Ratio 2.74
Current Ratio 3.20
Debt/Eq 7.08
LT Debt/Eq —
EPS (ttm) -1.09
EPS next Y -0.28
EPS Growth —
Revenue Growth 17.70%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-02-24
ROA -27.30%
ROE -55.50%
ROIC —
Gross Margin 34.28%
Oper. Margin -84.66%
Profit Margin -148.38%
Shs Outstand 411.96M
Shs Float 353.45M
Insider Own 0.40%
Instit Own 71.21%
Short Float 28.41%
Short Ratio 7.75
Short Interest 108.80M
52W High 5.63
vs 52W High -39.08%
52W Low 1.64
vs 52W Low 109.15%
Beta 0.76
Impl. Vol. 84.38%
Rel Volume 0.65
Avg Volume 15.67M
Volume 10.18M
Target (mean) $9.00
Tgt Median $9.50
Tgt Low $4.00
Tgt High $16.00
# Analysts 10
Recom Buy
Prev Close $3.44
Price $3.43
Change -0.29%
About

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$9.00
Mean price target
2. Current target
$3.43
Latest analyst target
3. DCF / Fair value
$-7.10
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.43
Low
$4.00
High
$16.00
Mean
$9.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-10 main Chardan Capital Buy → Buy $16
2026-03-05 main UBS Neutral → Neutral $4
2026-03-03 up Citizens Market Perform → Market Outperform $5
2026-02-25 main Barclays Overweight → Overweight $11
2026-02-25 up Citizens Market Perform → Market Outperform $5
2025-12-17 main Barclays Overweight → Overweight $10
2025-11-24 main Barclays Overweight → Overweight $9
2025-11-06 main Chardan Capital Buy → Buy $17
2025-10-29 main HC Wainwright & Co. Buy → Buy $9
2025-08-19 reit HC Wainwright & Co. Buy → Buy $20
2025-08-08 main Wells Fargo Overweight → Overweight $14
2025-08-08 main Chardan Capital Buy → Buy $20
2025-07-23 main Chardan Capital Buy → Buy $25
2025-05-16 down UBS Buy → Neutral $2
2025-05-12 main Goldman Sachs Buy → Buy $8
2025-05-12 main Mizuho Outperform → Outperform $10
2025-05-12 main Barclays Overweight → Overweight $4
2025-05-09 down JMP Securities Market Outperform → Market Perform —
2025-05-09 main Chardan Capital Buy → Buy $25
2025-05-09 main HC Wainwright & Co. Buy → Buy $20
News
RSS: Latest IOVA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-05 PURI RAJ K Officer — 39,059 — —
2026-03-05 BILINSKY IGOR P Chief Operating Officer — 31,246 — —
2026-03-05 VOGT FREDERICK G Chief Executive Officer — 62,493 — —
2026-03-05 GRAF FINCKENSTEIN FRIEDRICH Officer — 31,246 — —
2026-03-02 PURI RAJ K Officer — 5,470 — —
2026-03-02 BILINSKY IGOR P Chief Operating Officer — 12,307 — —
2026-03-02 VOGT FREDERICK G Chief Executive Officer — 52,087 — —
2026-03-02 GRAF FINCKENSTEIN FRIEDRICH Officer — 12,697 — —
2026-02-24 KIRBY DANIEL GORDON Officer — 120,000 — —
2026-02-10 KIRBY DANIEL GORDON Officer — 39,996 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
263.50
+60.60%
164.07
+13698.99%
1.19
0.00
Operating Revenue
268.00
+58.42%
169.17
+14092.11%
1.19
0.00
Cost Of Revenue
173.18
+85.72%
93.25
+8926.91%
1.03
0.00
Reconciled Cost Of Revenue
161.80
+95.46%
82.78
+7913.55%
1.03
0.00
Gross Profit
90.32
+27.53%
70.82
+45298.72%
0.16
0.00
Operating Expense
488.53
+4.81%
466.10
+1.17%
460.71
+15.50%
398.88
Research And Development
300.27
+8.70%
276.23
-17.10%
333.19
+13.03%
294.78
Selling General And Administration
152.32
+0.03%
152.27
+43.52%
106.10
+1.92%
104.10
General And Administrative Expense
—
—
—
104.10
Other Gand A
—
—
—
104.10
Total Expenses
661.72
+18.30%
559.35
+21.14%
461.75
+15.76%
398.88
Operating Income
-398.21
-0.74%
-395.28
+14.17%
-460.56
-15.46%
-398.88
Total Operating Income As Reported
-403.36
-2.04%
-395.28
+14.17%
-460.56
-15.46%
-398.88
EBITDA
-350.89
-1.06%
-347.21
+18.77%
-427.43
-13.15%
-377.74
Normalized EBITDA
-345.75
+0.42%
-347.21
+18.77%
-427.43
-13.15%
-377.74
Reconciled Depreciation
47.32
-1.55%
48.07
+45.11%
33.13
+56.74%
21.14
EBIT
-398.21
-0.74%
-395.28
+14.17%
-460.56
-15.46%
-398.88
Total Unusual Items
-5.14
0.00
0.00
—
Total Unusual Items Excluding Goodwill
-5.14
0.00
0.00
—
Special Income Charges
-5.14
0.00
0.00
—
Restructuring And Mergern Acquisition
5.14
0.00
0.00
—
Net Income
-390.98
-5.05%
-372.18
+16.18%
-444.04
-12.16%
-395.89
Pretax Income
-393.05
-4.81%
-375.00
+16.20%
-447.52
-13.04%
-395.89
Net Non Operating Interest Income Expense
10.31
-49.16%
20.27
+55.43%
13.04
+336.95%
2.98
Net Interest Income
10.31
-49.16%
20.27
+55.43%
13.04
+336.95%
2.98
Interest Income Non Operating
10.31
-49.16%
20.27
+55.43%
13.04
+336.95%
2.98
Interest Income
10.31
-49.16%
20.27
+55.43%
13.04
+336.95%
2.98
Other Income Expense
-5.14
—
—
—
Tax Provision
-2.07
+26.77%
-2.83
+18.71%
-3.48
0.00
Tax Rate For Calcs
0.00
-29.33%
0.00
-3.85%
0.00
0.00
Tax Effect Of Unusual Items
-0.03
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-390.98
-5.05%
-372.18
+16.18%
-444.04
-12.16%
-395.89
Net Income From Continuing Operation Net Minority Interest
-390.98
-5.05%
-372.18
+16.18%
-444.04
-12.16%
-395.89
Net Income From Continuing And Discontinued Operation
-390.98
-5.05%
-372.18
+16.18%
-444.04
-12.16%
-395.89
Net Income Continuous Operations
-390.98
-5.05%
-372.18
+16.18%
-444.04
-12.16%
-395.89
Normalized Income
-385.86
-3.68%
-372.18
+16.18%
-444.04
-12.16%
-395.89
Net Income Common Stockholders
-390.98
-5.05%
-372.18
+16.18%
-444.04
-12.16%
-395.89
Diluted EPS
-1.09
+14.84%
-1.28
+32.28%
-1.89
+24.10%
-2.49
Basic EPS
-1.09
+14.84%
-1.28
+32.28%
-1.89
+24.10%
-2.49
Basic Average Shares
357.35
+23.27%
289.88
+23.28%
235.13
+47.64%
159.26
Diluted Average Shares
357.35
+23.27%
289.88
+23.28%
235.13
+47.64%
159.26
Diluted NI Availto Com Stockholders
-390.98
-5.05%
-372.18
+16.18%
-444.04
-12.16%
-395.89
Depreciation Amortization Depletion Income Statement
35.94
-4.43%
37.60
+75.53%
21.42
—
Depreciation And Amortization In Income Statement
35.94
-4.43%
37.60
+75.53%
21.42
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
913.17
+0.30%
910.43
+16.67%
780.35
+17.53%
663.98
Current Assets
442.69
-3.14%
457.02
+48.46%
307.85
-35.75%
479.12
Cash Cash Equivalents And Short Term Investments
296.98
-8.28%
323.78
+15.69%
279.87
-40.69%
471.85
Cash And Cash Equivalents
163.08
+40.96%
115.69
+0.70%
114.89
-50.42%
231.73
Other Short Term Investments
133.90
-35.65%
208.09
+26.13%
164.98
-31.29%
240.11
Receivables
82.45
+18.90%
69.34
+45820.53%
0.15
0.00
Accounts Receivable
82.45
+18.90%
69.34
+45820.53%
0.15
0.00
Inventory
51.68
+0.31%
51.52
+396.72%
10.37
0.00
Raw Materials
31.68
+14.20%
27.74
0.00
—
Work In Process
5.04
-42.45%
8.77
+52.46%
5.75
0.00
Finished Goods
22.83
+52.06%
15.01
+224.72%
4.62
0.00
Prepaid Assets
—
—
—
—
Other Current Assets
11.58
-6.42%
12.38
-29.10%
17.46
+140.10%
7.27
Total Non Current Assets
470.48
+3.77%
453.41
-4.04%
472.50
+155.59%
184.87
Net PPE
177.01
+7.75%
164.28
-6.95%
176.54
-0.95%
178.25
Gross PPE
225.78
+12.72%
200.30
-2.03%
204.46
+4.87%
194.97
Accumulated Depreciation
-48.77
-35.40%
-36.02
-29.04%
-27.91
-66.96%
-16.72
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
15.04
+32.88%
11.32
-5.00%
11.92
+14.15%
10.44
Construction In Progress
35.65
+2.04%
34.94
+44.96%
24.10
+164.32%
9.12
Other Properties
84.70
-2.27%
86.67
-5.42%
91.64
-9.36%
101.10
Leases
90.39
+34.15%
67.38
-12.28%
76.80
+3.36%
74.31
Goodwill And Other Intangible Assets
279.32
-1.09%
282.40
+23.18%
229.26
0.00
Investments And Advances
—
—
—
0.00
Other Non Current Assets
14.15
+110.26%
6.73
-89.91%
66.70
+907.71%
6.62
Total Liabilities Net Minority Interest
214.59
+7.28%
200.02
+2.19%
195.74
+19.10%
164.34
Current Liabilities
138.36
+13.09%
122.34
+10.91%
110.31
+20.57%
91.48
Payables And Accrued Expenses
133.31
+21.81%
109.44
+6.75%
102.53
+29.95%
78.90
Payables
22.16
-19.45%
27.51
-16.95%
33.12
+24.51%
26.60
Accounts Payable
22.16
-19.45%
27.51
-16.95%
33.12
+24.51%
26.60
Current Accrued Expenses
111.16
+35.66%
81.94
+18.05%
69.41
+32.72%
52.30
Current Debt And Capital Lease Obligation
5.04
-60.89%
12.90
+65.82%
7.78
-38.21%
12.59
Current Debt
1.00
—
—
—
Current Capital Lease Obligation
4.04
-68.65%
12.90
+65.82%
7.78
-38.21%
12.59
Total Non Current Liabilities Net Minority Interest
76.23
-1.87%
77.68
-9.07%
85.43
+17.26%
72.86
Long Term Debt And Capital Lease Obligation
44.40
-2.12%
45.37
-33.37%
68.08
-6.55%
72.86
Long Term Debt
—
1.00
+0.00%
1.00
+0.00%
1.00
Long Term Capital Lease Obligation
44.40
+0.08%
44.37
-33.87%
67.08
-6.64%
71.86
Non Current Deferred Liabilities
31.83
-1.51%
32.31
+86.29%
17.35
0.00
Non Current Deferred Taxes Liabilities
31.83
-1.51%
32.31
+86.29%
17.35
0.00
Stockholders Equity
698.58
-1.66%
710.40
+21.52%
584.61
+17.01%
499.64
Common Stock Equity
698.58
-1.66%
710.40
+21.52%
584.61
+17.01%
499.63
Capital Stock
0.02
+18.75%
0.02
+14.29%
0.01
+27.27%
0.01
Common Stock
0.02
+30.77%
0.01
+18.18%
0.01
+37.50%
0.01
Preferred Stock
0.00
-33.33%
0.00
+0.00%
0.00
+0.00%
0.00
Share Issued
411.94
+34.95%
305.25
+19.18%
256.14
+36.38%
187.81
Ordinary Shares Number
411.94
+34.95%
305.25
+19.18%
256.14
+36.38%
187.81
Additional Paid In Capital
3,457.65
+11.68%
3,095.99
+19.33%
2,594.45
+25.40%
2,068.87
Retained Earnings
-2,775.53
-16.40%
-2,384.55
-18.49%
-2,012.38
-28.31%
-1,568.34
Gains Losses Not Affecting Retained Earnings
16.44
+1671.70%
-1.05
-141.41%
2.53
+380.04%
-0.90
Other Equity Adjustments
16.44
+1671.70%
-1.05
-141.41%
2.53
+380.04%
-0.90
Total Equity Gross Minority Interest
698.58
-1.66%
710.40
+21.52%
584.61
+17.01%
499.64
Total Capitalization
698.58
-1.80%
711.40
+21.48%
585.61
+16.97%
500.64
Working Capital
304.33
-9.07%
334.68
+69.42%
197.54
-49.04%
387.63
Invested Capital
699.58
-1.66%
711.40
+21.48%
585.61
+16.97%
500.63
Total Debt
49.44
-15.13%
58.26
-23.20%
75.86
-11.22%
85.45
Capital Lease Obligations
48.44
-15.40%
57.26
-23.51%
74.86
-11.35%
84.45
Net Tangible Assets
419.26
-2.04%
428.01
+20.44%
355.36
-28.88%
499.64
Tangible Book Value
419.26
-2.04%
428.00
+20.45%
355.35
-28.88%
499.63
Available For Sale Securities
—
—
—
—
Current Notes Payable
1.00
0.00
—
—
Investmentin Financial Assets
—
—
—
0.00
Other Inventories
-7.88
—
—
—
Preferred Stock Equity
0.00
-33.33%
0.00
+0.00%
0.00
+0.00%
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-302.41
+14.33%
-352.98
+2.44%
-361.82
-23.59%
-292.76
Cash Flow From Continuing Operating Activities
-302.41
+14.33%
-352.98
+2.44%
-361.82
-23.59%
-292.76
Net Income From Continuing Operations
-390.98
-5.05%
-372.18
+16.18%
-444.04
-12.16%
-395.89
Depreciation Amortization Depletion
47.32
-1.55%
48.07
+45.11%
33.13
+56.74%
21.14
Depreciation
24.25
+11.78%
21.69
-6.81%
23.28
+10.14%
21.14
Amortization Cash Flow
23.08
-12.52%
26.38
+167.83%
9.85
0.00
Depreciation And Amortization
47.32
-1.55%
48.07
+45.11%
33.13
+56.74%
21.14
Amortization Of Intangibles
23.08
-12.52%
26.38
+167.83%
9.85
0.00
Stock Based Compensation
61.58
-43.83%
109.63
+75.05%
62.62
-25.47%
84.02
Provisionand Write Offof Assets
13.40
—
—
—
Asset Impairment Charge
—
7.36
0.00
-100.00%
0.40
Deferred Tax
-2.07
+26.77%
-2.83
+18.71%
-3.48
0.00
Deferred Income Tax
-2.07
+26.77%
-2.83
+18.71%
-3.48
0.00
Operating Gains Losses
-0.19
-112.03%
1.61
+2202.86%
0.07
—
Net Foreign Currency Exchange Gain Loss
-0.24
-36.00%
-0.17
-350.00%
0.07
0.00
Gain Loss On Sale Of PPE
0.00
+100.00%
-5.57
0.00
0.00
Change In Working Capital
-24.27
+80.90%
-127.02
-1847.88%
-6.52
-125.48%
-2.89
Change In Receivables
-13.11
+81.05%
-69.19
-46335.57%
-0.15
0.00
Changes In Account Receivables
-13.11
+81.05%
-69.19
-46335.57%
-0.15
0.00
Change In Inventory
-14.21
+67.98%
-44.38
-338.64%
-10.12
0.00
Change In Prepaid Assets
-8.02
-279.70%
-2.11
+79.00%
-10.06
-372.39%
-2.13
Change In Payables And Accrued Expense
21.98
+2881.82%
0.74
-97.00%
24.60
+1984.92%
1.18
Change In Accrued Expense
28.64
+233.84%
8.58
-56.62%
19.77
+520.46%
-4.70
Change In Payable
-6.66
+15.05%
-7.84
-262.41%
4.83
-17.93%
5.88
Change In Account Payable
-6.66
+15.05%
-7.84
-262.41%
4.83
-17.93%
5.88
Change In Other Current Liabilities
-10.90
+9.72%
-12.07
-11.86%
-10.79
-455.82%
-1.94
Investing Cash Flow
47.50
+149.26%
-96.41
+37.90%
-155.24
-160.53%
256.45
Cash Flow From Continuing Investing Activities
47.50
+149.26%
-96.41
+37.90%
-155.24
-160.53%
256.45
Net PPE Purchase And Sale
-33.84
-205.68%
-11.07
+50.34%
-22.29
-9.13%
-20.43
Purchase Of PPE
-33.84
-205.68%
-11.07
+50.34%
-22.29
-9.13%
-20.43
Capital Expenditure
-33.84
-205.68%
-11.07
+50.34%
-22.29
-9.13%
-20.43
Net Investment Purchase And Sale
81.33
+348.20%
-32.77
-141.13%
79.68
-71.22%
276.88
Purchase Of Investment
-318.67
+30.84%
-460.77
-123.78%
-205.90
+16.24%
-245.82
Sale Of Investment
400.00
-6.54%
428.00
+49.87%
285.58
-45.36%
522.70
Net Business Purchase And Sale
0.00
+100.00%
-52.57
+75.28%
-212.63
0.00
Purchase Of Business
0.00
+100.00%
-52.57
+75.28%
-212.63
0.00
Financing Cash Flow
300.77
-23.01%
390.66
-15.62%
462.96
+143.47%
190.15
Cash Flow From Continuing Financing Activities
300.77
-23.01%
390.66
-15.62%
462.96
+143.47%
190.15
Net Issuance Payments Of Debt
—
—
0.00
0.00
Issuance Of Debt
—
—
0.00
0.00
Long Term Debt Issuance
—
—
0.00
0.00
Net Long Term Debt Issuance
—
—
0.00
0.00
Net Common Stock Issuance
306.31
-22.90%
397.30
-14.24%
463.28
+144.47%
189.50
Proceeds From Stock Option Exercised
1.52
-75.47%
6.22
+151.44%
2.47
-24.99%
3.30
Net Other Financing Charges
-7.06
+45.10%
-12.86
-360.04%
-2.79
-5.51%
-2.65
Changes In Cash
45.86
+178.10%
-58.72
-8.54%
-54.10
-135.17%
153.85
Effect Of Exchange Rate Changes
1.14
+311.46%
-0.54
+80.26%
-2.74
—
Beginning Cash Position
122.05
-32.69%
181.32
-23.87%
238.16
+182.47%
84.31
End Cash Position
169.06
+38.51%
122.05
-32.69%
181.32
-23.87%
238.16
Free Cash Flow
-336.24
+7.64%
-364.05
+5.22%
-384.11
-22.65%
-313.18
Amortization Of Securities
-7.20
+29.81%
-10.26
-184.63%
-3.60
-860.55%
0.47
Common Stock Issuance
306.31
-22.90%
397.30
-14.24%
463.28
+144.47%
189.50
Issuance Of Capital Stock
306.31
-22.90%
397.30
-14.24%
463.28
+144.47%
189.50
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category